125 related articles for article (PubMed ID: 1008080)
21. [Combination of fotemustine-dacarbazine and interferon alpha in the treatment of metastatic malignant melanoma].
Célérier P; Dreno B; Bureau B; Litoux P
Ann Dermatol Venereol; 1993; 120(6-7):437-40. PubMed ID: 8279787
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of disseminated malignant melanoma. Results are promising, but toxicity is high].
Brunet A
Pathol Biol (Paris); 1992 Dec; 40(9 Pt 2):960-3. PubMed ID: 1303493
[TBL] [Abstract][Full Text] [Related]
23. [5-year results of a chemo-immunotherapeutic treatment in stage-I and -II malignant melanoma].
Comella G; Mastro AA; Comella P; Castello G; De Simone G; Cerra R; Zarrilli D
Minerva Med; 1986 Mar; 77(13):507-10. PubMed ID: 3703343
[No Abstract] [Full Text] [Related]
24. Results of adjuvant BCG immunotherapy in malignant melanoma.
Wätzig V; Knopf B
Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442
[TBL] [Abstract][Full Text] [Related]
25. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
[No Abstract] [Full Text] [Related]
26. Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
Gutterman JU; Mavligit GM; Blumenshein G; Burgess MA; McBride CM; Hersh EM
Ann N Y Acad Sci; 1976; 277(00):135-59. PubMed ID: 1069546
[No Abstract] [Full Text] [Related]
27. Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
Kaufman SD; Cosimi AB; Wood WC; Carey RW
Recent Results Cancer Res; 1978; 68():380-6. PubMed ID: 752874
[No Abstract] [Full Text] [Related]
28. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
Newlands ES; Oon CJ; Roberts JT; Elliott P; Mould RF; Topham C; Madden FJ; Newton KA; Westbury G
Br J Cancer; 1976 Aug; 34(2):174-9. PubMed ID: 962994
[TBL] [Abstract][Full Text] [Related]
29. [Combination of surgery and immunotherapy in the treatment of melanoma. Experience of the National Institute of Oncology].
Beltrán-Ortega A; Ramírez-Ugalde MT; Mora-Tiscareño A
Gac Med Mex; 1978 Jan; 114(1):29-36. PubMed ID: 669131
[No Abstract] [Full Text] [Related]
30. Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
Veronesi U; Beretta G
Recent Results Cancer Res; 1978; 68():375-9. PubMed ID: 752873
[No Abstract] [Full Text] [Related]
31. Oral bacille Calmette Guérin immunostimulation in malignant melanoma.
MacGregor AB; Falk RE; Landi S; Ambus U; Langer B
Surg Gynecol Obstet; 1975 Nov; 141(5):747-54. PubMed ID: 1105837
[TBL] [Abstract][Full Text] [Related]
32. [Combined treatment of patients with metastases of skin melanoma using cryotherapy].
Iavorskiĭ VV; Karaseva VV; Tokareva ZI
Vopr Onkol; 1988; 34(7):799-803. PubMed ID: 3420821
[TBL] [Abstract][Full Text] [Related]
33. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
Agarwala SS; Neuberg D; Park Y; Kirkwood JM
Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
[TBL] [Abstract][Full Text] [Related]
34. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
[TBL] [Abstract][Full Text] [Related]
35. Serum associated leucocyte locomotion inhibition and leucocyte motility in malignant melanoma: effect of BCG treatment.
Zielinski C; Pehamberger H; Endler AT; Knapp W
Clin Exp Immunol; 1979 Oct; 38(1):92-8. PubMed ID: 393441
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy of malignant melanoma with vaccinia virus.
Roenigk HH; Deodhar S; St Jacques R; Burdick K
Arch Dermatol; 1974 May; 109(5):668-73. PubMed ID: 4828533
[No Abstract] [Full Text] [Related]
37. Progress of immunotherapy in the treatment of malignant melanoma.
Ariyan S
Yale J Biol Med; 1975 Nov; 48(5):423-9. PubMed ID: 1108459
[No Abstract] [Full Text] [Related]
38. BCG in cancer therapy: patient responses to BCG therapy for malignant melanoma.
Sullivan BP
Am J Nurs; 1979 Feb; 79(2):320-4. PubMed ID: 254539
[No Abstract] [Full Text] [Related]
39. Changes in the rosette forming capacity of lymphocytes after surgery or surgery and immunochemotherapy of malignant melanoma in man.
Hadjikirova M; Boeva M; Ikonopisov R
Biomed Pharmacother; 1982; 36(5):257-9. PubMed ID: 7168802
[TBL] [Abstract][Full Text] [Related]
40. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
Karakousis CP; Didolkar MS; Han T
Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]